高级检索
当前位置: 首页 > 详情页

Handgrip weakness, systemic inflammation indicators, and overall survival in lung cancer patients with well performance status: A large multicenter observational study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China [3]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China [4]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, China [5]Department of Epidemiology and Statistics, Henan Key Laboratory of Tumor Epidemiology College of Public Health, Zhengzhou University, Zhengzhou, Henan, China [6]The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China [7]Liaocheng University, Liaocheng, China [8]The First Affiliated Hospital of Kunming Medical University, Yunnan, China [9]Affiliated Hospital of Yunnan University, Kunming, China [10]Yunnan University, Kunming, China [11]General Surgery Clinical Medical Center of Yunnan Province, Kunming, China [12]Department of Nutrition, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China [13]Cancer Center of the First Hospital of Jilin University, Changchun, China
出处:
ISSN:

关键词: ECOG handgrip weakness inflammation indicators lung cancer prognosis

摘要:
Background Systemic inflammation and handgrip weakness have been used to predict mortality in many cancers. The purpose of current study was to evaluate the association of co-occurrence of inflammation indicators and handgrip weakness with overall survival (OS) of lung cancer (LC) patients with good performance status. Methods The cutoff points for handgrip strength (HGS) and the four inflammation indicators were calculated using Maxstat. The time-dependent receiver operating characteristic curve and C-index were used to select optimal inflammation indicator for predicting OS of LC patients. The Cox proportional hazard regression model was used to calculate the hazard ratio (HR) of mortality. Kaplan-Meier curves were constructed to evaluate the association of indicators and the OS of LC patients. Results Among the 1951 patients, the mean +/- standard deviation (SD) age was 60.6 +/- 9.9 years, and 1300 (66.6%) patients were male. In patients with good performance status (PS), handgrip weakness (HR, 1.49; 95% confidence interval [95% CI], 1.30-1.70, p < 0.001) and low advanced lung cancer inflammation index (ALI) (HR, 2.05; 95%CI, 1.79-2.34, p < 0.001), high systemic immune-inflammation index (SII) (HR, 1.91; 95%CI, 1.66-2.19, p < 0.001), high platelet: lymphocyte ratio (PLR) (HR, 1.60; 95%CI, 1.40-1.82, p < 0.001), or high neutrophil: lymphocyte ratio (NLR) (HR, 2.01; 95%CI, 1.76-2.30, p < 0.001) were associated with increased mortality risk of LC patients. ALI had better C-index (0.624) and time-AUC in the prediction of OS in LC patients with good PS than other three combinations. The co-occurrence of handgrip weakness and low ALI more than doubled the risk of death in LC with good PS (HR, 2.44; 95% CI, 2.06-2.89, p < 0.001). Conclusion In LC patients who have good PS, patients with combined handgrip weakness and low ALI have the worst prognosis. The Trial Registration Number ChiCTR1800020329.

基金:

基金编号: ZX2019-03-03 2022YFC2009600

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China [3]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China [4]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, China
通讯作者:
通讯机构: [1]Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China [2]National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital, Capital Medical University, Beijing, China [3]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China [4]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, China [*1]Department of Gastrointestinal Surgery/Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53661 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)